Greenwich LifeSciences, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
3Greenwich LifeSciences's Business Model
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
About Greenwich LifeSciences
Website: https://greenwichlifesciences.com
CEO (Chief Executive Officer): Dr. Jaye L. Thompson Ph.D.
IPO date: 2020-09-25
Contact
Country: US
Address: Building 14
City: Stafford
State: TX
Phone: 832 819 3232
Zip Code: 77477
Other
CIK: 0001799788
ISIN: US3968791083
CUSIP: 396879108
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
